Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sionna Therapeutics, Inc. - Common Stock (NQ:SION)

5.190 +0.040 (+0.78%)
Streaming Delayed Price Updated: 12:29 PM EDT, Sep 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sionna Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
From Pomerantz LLP
Via GlobeNewswire
News headline image
Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
From Pomerantz LLP
Via GlobeNewswire
News headline image
SIONNA THERAPEUTICS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Sionna Therapeutics Inc on Behalf of Sionna Therapeutics Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
From Pomerantz LLP
Via GlobeNewswire
News headline image
Investigation Launched into Sionna Therapeutics, Inc. (SION), Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
News headline image
Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Sionna Therapeutics, Inc. (SION) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Robbins LLP is Investigating the Recent Stock Drop of Sionna Therapeutics; Contact the Firm for Information
From Robbins LLP
Via Business Wire
News headline image
SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
SION Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Sionna Therapeutics (SION)
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics Reports Second Quarter 2026 Financial Results
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics Reports First Quarter 2026 Financial Results
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis
Topline data is on track for anticipated readout in the summer of 2026 
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics to Participate in Upcoming December Investor Conferences
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics Reports Third Quarter 2025 Financial Results
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics to Participate in Upcoming November Investor Conferences
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference
From Sionna Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.